Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab

BACKGROUND: Immune checkpoint inhibitors (ICPIs), used to treat different advanced malignancies, are associated with a wide range of immune-related adverse reactions (irAEs) that deserve close monitoring of patients. Gastrointestinal reactions and hepatotoxicity may occur, which warrant careful eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hao Chi, Luo, Wenyi, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380028/
https://www.ncbi.nlm.nih.gov/pubmed/30777137
http://dx.doi.org/10.1186/s40425-019-0532-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380028/
https://www.ncbi.nlm.nih.gov/pubmed/30777137
http://dx.doi.org/10.1186/s40425-019-0532-1

Ejemplares similares